Close
Help




JOURNAL

Clinical Medicine Insights: Therapeutics

Azelastine HCl: A Review of the Old and New Formulations

Submit a Paper


Clinical Medicine Insights: Therapeutics 2010:2 427-437

Review

Published on 11 May 2010

DOI: 10.4137/CMT.S3865


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Therapeutics

Abstract

Azelastine HCl (Astelin™) is an intranasal antihistamine indicated for use in patients with seasonal allergic rhinitis (SAR) and non-allergic vasomotor rhinitis (VMR). A side effect of this medication is bitter taste which many patients find aversive. To address the issue of bitter taste, azelastine has been reformulated to include sucralose and sorbitol. The new formulation (Astepro™ 0.1%) is approved for seasonal and perennial allergic rhinitis and has been demonstrated to have comparable pharmacokinetics, pharmacodynamics and therapeutic efficacy compared to Astelin. More recently, Astepro at a concentration 0.15% has been approved for once a day use. This review will provide an overview of the old and new formulations of Azelastine.



Downloads

PDF  (712.69 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)




What Your Colleagues Say About Clinical Medicine Insights: Therapeutics
It is my pleasure to confirm that we had a very pleasant experience by publishing our article in Clinical Medicine Insights: Therapeutics.  The review process was highly efficient and the reviewers' comments useful and constructive.  I am sure that this is the kind of publication needed by the scientific community.  I am looking forward future collaborations.
Dr Federico Navarro Sarabia (University Hospital Virgen Macarena, Sevilla, Spain)
More Testimonials

Quick Links


New article and journal news notification services